Interplay between primary familial brain calcification-associated SLC20A2 and XPR1 phosphate transporters requires inositol polyphosphates for control of cellular phosphate homeostasis.

ATP SPX domain anion transport cell metabolism efflux transporter energy metabolism inositol phosphate inositol pyrophosphate metabolic regulation phosphate homeostasis phosphate transporter primary familial brain calcification (PFBC) solute carrier family 20 member 2 (SLC20A2) xenotropic and polytropic retrovirus receptor 1 (XPR1)

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
10 07 2020
Historique:
received: 08 10 2019
revised: 09 05 2020
pubmed: 13 5 2020
medline: 14 1 2021
entrez: 13 5 2020
Statut: ppublish

Résumé

Solute carrier family 20 member 2 (SLC20A2) and xenotropic and polytropic retrovirus receptor 1 (XPR1) are transporters with phosphate uptake and efflux functions, respectively. Both are associated with primary familial brain calcification (PFBC), a genetic disease characterized by cerebral calcium-phosphate deposition and associated with neuropsychiatric symptoms. The association of the two transporters with the same disease suggests that they jointly regulate phosphate fluxes and cellular homeostasis, but direct evidence is missing. Here, we found that cross-talk between SLC20A2 and XPR1 regulates phosphate homeostasis, and we identified XPR1 as a key inositol polyphosphate (IP)-dependent regulator of this process. We found that overexpression of WT SLC20A2 increased phosphate uptake, as expected, but also unexpectedly increased phosphate efflux, whereas PFBC-associated SLC20A2 variants did not. Conversely, SLC20A2 depletion decreased phosphate uptake only slightly, most likely compensated for by the related SLC20A1 transporter, but strongly decreased XPR1-mediated phosphate efflux. The SLC20A2-XPR1 axis maintained constant intracellular phosphate and ATP levels, which both increased in XPR1 KO cells. Elevated ATP levels are a hallmark of altered inositol pyrophosphate (PP-IP) synthesis, and basal ATP levels were restored after phosphate efflux rescue with WT XPR1 but not with XPR1 harboring a mutated PP-IP-binding pocket. Accordingly, inositol hexakisphosphate kinase 1-2 (

Identifiants

pubmed: 32393577
pii: S0021-9258(17)48959-9
doi: 10.1074/jbc.RA119.011376
pmc: PMC7363132
doi:

Substances chimiques

Inositol Phosphates 0
Receptors, G-Protein-Coupled 0
Receptors, Virus 0
SLC20A2 protein, human 0
Sodium-Phosphate Cotransporter Proteins, Type III 0
XPR1 protein, human 0
Xenotropic and Polytropic Retrovirus Receptor 0
Adenosine Triphosphate 8L70Q75FXE
Phosphotransferases (Phosphate Group Acceptor) EC 2.7.4.-
IP6K1 protein, human EC 2.7.4.21
inositol hexakisphosphate kinase EC 2.7.4.21

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9366-9378

Subventions

Organisme : Medical Research Council
ID : MC_UU_00012/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T028904/1
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : P01 DK032094
Pays : United States

Informations de copyright

© 2020 López-Sánchez et al.

Déclaration de conflit d'intérêts

Conflict of interest—J.-L. B. and M. S. are inventors on patents describing the use of RBD ligands; M. S. is the co-founder of METAFORA-biosystems, a start-up company that focuses on metabolite transporters under physiological and pathological conditions.

Références

Science. 2011 Nov 11;334(6057):802-5
pubmed: 22076377
Nat Genet. 1999 Feb;21(2):216-9
pubmed: 9988277
Neurochem Res. 2015 Dec;40(12):2583-99
pubmed: 25947369
Kidney Int. 1996 Apr;49(4):959-63
pubmed: 8691744
Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):586-94
pubmed: 26129893
Pflugers Arch. 2004 Feb;447(5):647-52
pubmed: 12759754
Nat Genet. 2012 Feb 12;44(3):254-6
pubmed: 22327515
Cell Mol Life Sci. 2011 Jan;68(2):205-18
pubmed: 20848155
Cardiovasc Res. 2018 Mar 15;114(4):590-600
pubmed: 29514202
Trends Biochem Sci. 2017 Mar;42(3):219-231
pubmed: 27876550
Neurology. 2013 Jan 8;80(2):181-7
pubmed: 23255827
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3568-3574
pubmed: 32019887
Nat Genet. 2013 Sep;45(9):1077-82
pubmed: 23913003
J Biol Chem. 2018 Feb 9;293(6):2102-2114
pubmed: 29233890
Cell Rep. 2013 Jun 27;3(6):1866-73
pubmed: 23791524
J Neurol Sci. 2018 May 15;388:150-154
pubmed: 29627011
J Bone Miner Res. 2019 Jun;34(6):1101-1114
pubmed: 30721528
J Bone Miner Metab. 2010 Mar;28(2):139-48
pubmed: 19795094
Am J Physiol Renal Physiol. 2014 Jun 1;306(11):F1275-84
pubmed: 24740787
Pflugers Arch. 2009 Oct;458(6):1151-61
pubmed: 19506901
Cell Mol Life Sci. 2006 Mar;63(5):552-64
pubmed: 16429326
J Am Soc Nephrol. 2013 Feb;24(3):353-63
pubmed: 23291474
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1385-90
pubmed: 9990033
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11968-11973
pubmed: 29078269
Science. 2016 May 20;352(6288):986-90
pubmed: 27080106
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7071-5
pubmed: 8041748
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):78-82
pubmed: 8278411
Sci Rep. 2017 Mar 27;7:45214
pubmed: 28345672
J Am Soc Nephrol. 2004 Nov;15(11):2857-67
pubmed: 15504939
Brain. 2013 Nov;136(Pt 11):3395-407
pubmed: 24065723
Cell. 2003 Nov 14;115(4):449-59
pubmed: 14622599
J Biol Chem. 2019 Jul 26;294(30):11597-11608
pubmed: 31186349
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2625-32
pubmed: 23968976
N Engl J Med. 2010 Jun 24;362(25):2399-409
pubmed: 20573928
Curr Opin Biotechnol. 2018 Feb;49:156-162
pubmed: 28889038
Nat Genet. 2015 Jun;47(6):579-81
pubmed: 25938945
Acta Neuropathol. 2005 Jun;109(6):643-53
pubmed: 15937691
Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90
pubmed: 2631796
J Biol Chem. 2017 Mar 17;292(11):4544-4555
pubmed: 28126903
J Mol Neurosci. 2017 Feb;61(2):215-220
pubmed: 27943094
Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):927-32
pubmed: 9927670
Eur J Hum Genet. 2018 Oct;26(10):1462-1477
pubmed: 29955172
J Neurol. 2016 Aug;263(8):1559-64
pubmed: 27230854
Sci Rep. 2019 May 1;9(1):6776
pubmed: 31043717
Mol Plant. 2019 Nov 4;12(11):1463-1473
pubmed: 31419530
Circ Res. 2006 Apr 14;98(7):905-12
pubmed: 16527991
Neurogenetics. 2016 Apr;17(2):125-30
pubmed: 26660102
Genomics. 1999 Dec 1;62(2):281-4
pubmed: 10610722
Neuron. 2018 Jun 27;98(6):1116-1123.e5
pubmed: 29910000
J Virol. 2005 May;79(10):6560-4
pubmed: 15858043
Brain. 2019 Jun 1;142(6):1573-1586
pubmed: 31009047
Eur J Hum Genet. 2016 Nov;24(11):1630-1634
pubmed: 27245298
Brain. 2020 Feb 1;143(2):491-502
pubmed: 31851307
Biochem J. 2013 Jun 15;452(3):369-79
pubmed: 23725456
Cell Growth Differ. 1990 Mar;1(3):119-27
pubmed: 2078500
J Virol. 2012 Feb;86(3):1661-9
pubmed: 22090134
J Biol Chem. 1994 Oct 14;269(41):25426-31
pubmed: 7929240
FEBS Lett. 2014 Jan 31;588(3):482-9
pubmed: 24374333
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14564-9
pubmed: 9826740
J Neurol Sci. 2017 Apr 15;375:245-247
pubmed: 28320140
Nat Protoc. 2006;1(5):2416-22
pubmed: 17406485
Brain Pathol. 2017 Jan;27(1):64-76
pubmed: 26822507

Auteurs

Uriel López-Sánchez (U)

Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.
Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS, Montpellier, France.

Sandrine Tury (S)

Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.

Gaël Nicolas (G)

Normandie Univ, UNIROUEN, Inserm U1245, and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

Miranda S Wilson (MS)

MRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.

Snejana Jurici (S)

Department of Neurology, Perpignan Hospital, Perpignan, France.

Xavier Ayrignac (X)

Department of Neurology, Montpellier University Hospital, Montpellier, France.

Valérie Courgnaud (V)

Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS, Montpellier, France.

Adolfo Saiardi (A)

MRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.

Marc Sitbon (M)

Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS, Montpellier, France marc.sitbon@igmm.cnrs.fr jean-luc.battini@irim.cnrs.fr.

Jean-Luc Battini (JL)

Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France marc.sitbon@igmm.cnrs.fr jean-luc.battini@irim.cnrs.fr.
Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH